Incomplete Freund's adjuvant

Generic Name: Incomplete Freund's adjuvant

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: Y9DQK7DB5U

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Gastric Cancer

HER-Vaxx, a HER2-targeting vaccine, showed safety and immunogenicity in a phase II trial for HER2-overexpressing gastric cancer, inducing HER2-specific antibodies correlating with tumor reduction, phosphorylation inhibition, and ADCC, enhancing SOC chemotherapy efficacy.

Related Clinical Trials:

A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients with HER2 Positive Advanced Gastric Cancer

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy